ZIOPHARM Oncology Inc (ZIOP) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) from a hold rating to a buy rating in a report released on Friday. The firm currently has $5.25 target price on the biotechnology company’s stock.

According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “

Several other equities research analysts have also commented on ZIOP. ValuEngine lowered ZIOPHARM Oncology from a hold rating to a sell rating in a research note on Monday, August 14th. BidaskClub upgraded ZIOPHARM Oncology from a sell rating to a hold rating in a research note on Tuesday, August 8th. Finally, HC Wainwright set a $10.00 price objective on ZIOPHARM Oncology and gave the stock a buy rating in a research note on Tuesday, August 1st. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. ZIOPHARM Oncology has an average rating of Hold and an average target price of $12.58.

Shares of ZIOPHARM Oncology (ZIOP) opened at $4.51 on Friday. ZIOPHARM Oncology has a 12 month low of $4.03 and a 12 month high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13). The company had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $1.66 million. The company’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter last year, the company earned ($0.11) earnings per share. research analysts anticipate that ZIOPHARM Oncology will post -0.54 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://transcriptdaily.com/2017/11/14/ziopharm-oncology-inc-ziop-upgraded-at-zacks-investment-research.html.

In other news, CEO Laurence James Neil Cooper bought 6,440 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The stock was bought at an average price of $4.68 per share, with a total value of $30,139.20. Following the acquisition, the chief executive officer now owns 1,083,731 shares of the company’s stock, valued at approximately $5,071,861.08. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 10.40% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Canada Pension Plan Investment Board bought a new position in ZIOPHARM Oncology in the 2nd quarter worth $1,010,000. Tudor Investment Corp ET AL boosted its holdings in ZIOPHARM Oncology by 390.4% in the 2nd quarter. Tudor Investment Corp ET AL now owns 63,304 shares of the biotechnology company’s stock worth $394,000 after buying an additional 50,395 shares during the period. Vanguard Group Inc. boosted its holdings in ZIOPHARM Oncology by 7.6% in the 2nd quarter. Vanguard Group Inc. now owns 7,864,470 shares of the biotechnology company’s stock worth $48,917,000 after buying an additional 553,933 shares during the period. Swiss National Bank boosted its holdings in ZIOPHARM Oncology by 21.3% in the 2nd quarter. Swiss National Bank now owns 218,920 shares of the biotechnology company’s stock worth $1,362,000 after buying an additional 38,500 shares during the period. Finally, TIAA CREF Investment Management LLC boosted its holdings in ZIOPHARM Oncology by 6.8% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 350,435 shares of the biotechnology company’s stock worth $2,180,000 after buying an additional 22,348 shares during the period. 41.88% of the stock is owned by institutional investors.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply